AI Engines For more Details: Perplexity Kagi Labs You
Edema: Torsemide helps reduce excess fluid accumulation in the body by increasing urine production. It is commonly prescribed to manage edema associated with conditions such as congestive heart failure, liver cirrhosis, and kidney disorders. By promoting diuresis, torsemide can alleviate symptoms such as swelling, shortness of breath, and weight gain caused by fluid retention.
Hypertension: Torsemide is sometimes used as an adjunct therapy to manage hypertension, particularly in cases where other antihypertensive medications are ineffective or insufficient. By promoting diuresis, torsemide helps lower blood pressure by reducing blood volume and relieving pressure on the blood vessel walls.
Congestive Heart Failure: Torsemide is frequently prescribed as part of the treatment regimen for congestive heart failure (CHF) to alleviate symptoms and improve cardiac function. By reducing fluid overload and decreasing the workload on the heart, torsemide can help relieve symptoms such as shortness of breath, fatigue, and swelling in individuals with CHF.
Liver Cirrhosis: Patients with liver cirrhosis often experience fluid retention due to impaired liver function. Torsemide may be prescribed to help manage ascites, a common complication of liver cirrhosis characterized by fluid accumulation in the abdominal cavity. By increasing urine output, torsemide can help reduce ascites and improve symptoms.
Kidney Disorders: Torsemide may be used to manage edema associated with various kidney disorders, including nephrotic syndrome and chronic kidney disease. By promoting diuresis, torsemide helps remove excess fluid from the body, thereby reducing swelling and relieving symptoms.
Renal Impairment: Torsemide is preferred over other diuretics in patients with impaired kidney function because it is primarily eliminated through non-renal pathways. However, dosing adjustments may be necessary in individuals with renal impairment to prevent potential adverse effects and optimize therapeutic efficacy.
Hyperkalemia: Torsemide can cause electrolyte imbalances, including hypokalemia (low potassium levels), which may be beneficial in individuals with hyperkalemia (high potassium levels). By promoting potassium excretion through urine, torsemide can help normalize potassium levels in patients with certain medical conditions.
Pulmonary Edema: Torsemide may be used as part of the treatment for acute pulmonary edema, a medical emergency characterized by fluid accumulation in the lungs. By reducing fluid overload and improving lung function, torsemide can help alleviate respiratory distress and improve oxygenation.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
0 | 1 | Bacteroides humanifaecis | species | Decreases |
0 | 1 | Bacteroides sp. CACC 737 | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
0 | 1 | Bacteroides sp. D2 | species | Decreases |
0 | 1 | Bacteroides luhongzhouii | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
0 | 1 | Bacteroides sp. M10 | species | Decreases |
0 | 1 | Bacteroides sp. HF-162 | species | Decreases |
0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
0 | 1 | Eubacterium callanderi | species | Decreases |
0 | 1 | Bacteroides sp. A1C1 | species | Decreases |
0 | 1 | Enterocloster asparagiformis | species | Decreases |
0 | 1 | Eubacterium limosum | species | Decreases |
0 | 1 | Bacteroides faecium | species | Decreases |
0 | 1 | Amedibacterium intestinale | species | Decreases |
0 | 1 | Ruthenibacterium lactatiformans | species | Decreases |
0 | 1 | Hungatella hathewayi | species | Decreases |
0 | 1 | Streptococcus pasteurianus | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
0 | 1 | Eubacterium maltosivorans | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
0 | 1 | Bacteroides xylanisolvens | species | Decreases |
0 | 1 | Bacteroides caecimuris | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
0 | 1 | Ruminococcus gauvreauii | species | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
ADHD | 1.9 | 1.9 | |
Age-Related Macular Degeneration and Glaucoma | 0.2 | -0.2 | |
Allergic Rhinitis (Hay Fever) | 1 | 0.7 | 0.43 |
Allergies | 2.1 | 1.1 | 0.91 |
Allergy to milk products | 0.8 | 0.7 | 0.14 |
Alopecia (Hair Loss) | 0.4 | 0.4 | |
Alzheimer's disease | 3.6 | 1.8 | 1 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.4 | 0.75 |
Ankylosing spondylitis | 1.3 | 1 | 0.3 |
Anorexia Nervosa | 0.3 | 0.8 | -1.67 |
Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
Asthma | 1.6 | 0.7 | 1.29 |
Atherosclerosis | 1.4 | 0.1 | 13 |
Atrial fibrillation | 1 | 0.7 | 0.43 |
Autism | 3.2 | 2.7 | 0.19 |
Autoimmune Disease | 0.2 | 0 | 0 |
Barrett esophagus cancer | 0.5 | 0.1 | 4 |
benign prostatic hyperplasia | 0.1 | 0.4 | -3 |
Biofilm | 1.2 | 1.2 | |
Bipolar Disorder | 0.7 | 0.7 | |
Brain Trauma | 0.2 | 0.4 | -1 |
Breast Cancer | 0.8 | 0.8 | |
Cancer (General) | 0.5 | 0.8 | -0.6 |
Carcinoma | 1.8 | 0.6 | 2 |
Celiac Disease | 1.2 | 0.7 | 0.71 |
Cerebral Palsy | 0.6 | 0.4 | 0.5 |
Chronic Fatigue Syndrome | 2.7 | 1.4 | 0.93 |
Chronic Kidney Disease | 2.3 | 0.3 | 6.67 |
Chronic Lyme | 0.6 | 0.4 | 0.5 |
Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.5 | 1 |
Chronic Urticaria (Hives) | 0.4 | 0.5 | -0.25 |
Coagulation / Micro clot triggering bacteria | 0.6 | 0.1 | 5 |
Cognitive Function | 0.6 | 0.1 | 5 |
Colorectal Cancer | 3.4 | 0.7 | 3.86 |
Constipation | 0.7 | 0.7 | |
Coronary artery disease | 0.6 | 0.8 | -0.33 |
COVID-19 | 4.2 | 3.8 | 0.11 |
Crohn's Disease | 4 | 1.6 | 1.5 |
Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
cystic fibrosis | 0.3 | 0.4 | -0.33 |
d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
deep vein thrombosis | 1.4 | 0.4 | 2.5 |
Denture Wearers Oral Shifts | 0.8 | 0.8 | |
Depression | 4.3 | 1.5 | 1.87 |
Dermatomyositis | 0.1 | 0.1 | |
Eczema | 0.9 | 0.6 | 0.5 |
Endometriosis | 1 | 0.2 | 4 |
Eosinophilic Esophagitis | 0.5 | 0.1 | 4 |
Epilepsy | 1.8 | 1.2 | 0.5 |
erectile dysfunction | 1 | 1 | |
Fibromyalgia | 1 | 1 | 0 |
Functional constipation / chronic idiopathic constipation | 2.2 | 1.8 | 0.22 |
gallstone disease (gsd) | 1.1 | 0.5 | 1.2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.6 | 0.1 | 15 |
Generalized anxiety disorder | 1.5 | 0.6 | 1.5 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0.1 | -0.1 | |
Gout | 1.2 | 0.1 | 11 |
Graves' disease | 0.6 | 0.5 | 0.2 |
Gulf War Syndrome | 0.1 | 1.2 | -11 |
Halitosis | 1.5 | 0.1 | 14 |
Hashimoto's thyroiditis | 1.5 | 0.7 | 1.14 |
Heart Failure | 2.4 | 0.1 | 23 |
hemorrhagic stroke | 0.7 | 0.7 | |
Hidradenitis Suppurativa | 0.9 | 0.9 | |
High Histamine/low DAO | 0.4 | 0.4 | |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.2 | 0.5 |
hyperglycemia | 0.5 | 0.8 | -0.6 |
Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
hypertension (High Blood Pressure | 1.6 | 1.5 | 0.07 |
Hypothyroidism | 0.1 | 0.1 | |
Hypoxia | 0.8 | 0.8 | |
IgA nephropathy (IgAN) | 1.1 | 2 | -0.82 |
Inflammatory Bowel Disease | 4.5 | 2.2 | 1.05 |
Insomnia | 0.5 | 0.8 | -0.6 |
Intelligence | 1.2 | 1.2 | |
Intracranial aneurysms | 1 | 0.1 | 9 |
Irritable Bowel Syndrome | 3.5 | 2.3 | 0.52 |
ischemic stroke | 0.9 | 0.5 | 0.8 |
Liver Cirrhosis | 2 | 1.5 | 0.33 |
Long COVID | 3.1 | 1.7 | 0.82 |
Low bone mineral density | 0.1 | -0.1 | |
Lung Cancer | 0.7 | 0.2 | 2.5 |
Lymphoma | 0.1 | 0.1 | |
Mast Cell Issues / mastitis | 0.8 | 0.8 | |
ME/CFS with IBS | 0.1 | 0.4 | -3 |
ME/CFS without IBS | 0.3 | 0.8 | -1.67 |
membranous nephropathy | 0.1 | 0.1 | |
Menopause | 0.7 | 0.1 | 6 |
Metabolic Syndrome | 2.7 | 2.6 | 0.04 |
Mood Disorders | 4 | 1.5 | 1.67 |
multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
Multiple Sclerosis | 1.9 | 1.5 | 0.27 |
Multiple system atrophy (MSA) | 0.4 | 0.4 | |
myasthenia gravis | 0.2 | 0 | 0 |
neuropathic pain | 0.7 | -0.7 | |
Neuropathy (all types) | 0.2 | 0.3 | -0.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2 | 0.6 | 2.33 |
NonCeliac Gluten Sensitivity | 0.6 | 0.4 | 0.5 |
Obesity | 2.8 | 2.7 | 0.04 |
obsessive-compulsive disorder | 3.3 | 1 | 2.3 |
Osteoarthritis | 1.5 | 0.5 | 2 |
Osteoporosis | 0.5 | 0.6 | -0.2 |
pancreatic cancer | 0.7 | 0.1 | 6 |
Parkinson's Disease | 2.7 | 1.7 | 0.59 |
Polycystic ovary syndrome | 2.8 | 0.6 | 3.67 |
Postural orthostatic tachycardia syndrome | 0 | 0 | |
Premenstrual dysphoric disorder | 0.2 | -0.2 | |
primary biliary cholangitis | 0.1 | 1.2 | -11 |
Primary sclerosing cholangitis | 1.3 | 0.8 | 0.63 |
Psoriasis | 0.8 | 1.2 | -0.5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.6 | 1.2 | 0.33 |
Rosacea | 0.2 | 0 | 0 |
Schizophrenia | 2 | 0.7 | 1.86 |
scoliosis | 0.2 | 0.2 | |
Sjögren syndrome | 0.4 | 1.2 | -2 |
Sleep Apnea | 0.5 | 0.4 | 0.25 |
Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1.2 | |
Stress / posttraumatic stress disorder | 1.4 | 0.7 | 1 |
Systemic Lupus Erythematosus | 1.8 | 0.1 | 17 |
Tic Disorder | 0.3 | 0.3 | |
Tourette syndrome | 0.2 | 0.4 | -1 |
Type 1 Diabetes | 1.9 | 0.7 | 1.71 |
Type 2 Diabetes | 2.9 | 3.4 | -0.17 |
Ulcerative colitis | 2.4 | 3.8 | -0.58 |
Unhealthy Ageing | 3.2 | 0.3 | 9.67 |
Vitiligo | 1 | 0.3 | 2.33 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]